Navigation Links
Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform
Date:3/30/2009

ST. LOUIS and MOUNTAIN VIEW, Calif., March 31 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement to supply high quality services and oligonucleotides to Gene Oracle, an innovative gene synthesis company. Under the terms of the agreement, Sigma-Aldrich will be the exclusive supplier of custom oligonucleotides for Gene Oracle, and the two Companies will engage in co-marketing efforts to promote the GeneIOS system and their expert gene synthesis services (http://www.sigma.com/oligos).

The GeneIOS system is unique in the market because it enables researchers to design and create synthetic genes quickly, accurately and at a lower cost than traditional gene synthesis service companies.

"Our partnership with Gene Oracle is focused on providing researchers with an optimal solution for their gene synthesis needs. Sigma-Aldrich has earned the research community's trust with our consistently high quality DNA oligonucleotides that we believe are an ideal complement to Gene Oracle's gene synthesis platform," said Khalil Arar, business development director for Sigma-Aldrich Custom Products. "We are proud to be the exclusive supplier of oligonucleotides to Gene Oracle, and we look forward to building awareness of our joint services through co-marketing efforts."

"Gene Oracle is focused on expanding the use and role of GeneIOS in the gene synthesis market," said Ken Mitchell, chief financial officer of Gene Oracle, "and with Sigma-Aldrich's global reach, plus their high quality oligonucleotides, the relationship is expected to provide Gene Oracle with not only strong marketing support but also high quality building blocks for our GeneIOS synthesis solution."

Sigma-Aldrich's oligonucleotides are an integral component of the Gene Oracle gene synthesis platform. After customers design an optimized gene sequence using the GeneIOS software, incorporating desired protein expression and other factors such as protein binding sites, Sigma-Aldrich can generate high quality oligonucleotides that can be easily assembled to create synthetic genes within a single day. Sigma-Aldrich guarantees the quality of its oligonucleotides, making them an ideal component of the GeneIOS solution.

Sigma-Aldrich offers a comprehensive collection of customized oligonucleotide services, from DNA oligos and probes to RNA and siRNA oligos and peptide library synthesis. For more information on Sigma-Aldrich custom oligonucleotides, or to order, please visit http://www.sigma.com/oligos.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About Gene Oracle: Founded in 2004, Gene Oracle Inc. is a privately held Mountain View, California-based corporation focused on developing and commercializing innovative products and services for the life science research market. Gene Oracle manufactures custom synthetic genes, and provides molecular biology consulting services to pharmaceutical, biotechnology, and academic research institutions. More information about GeneIOS is available at the Company's website at https://www.geneoracle.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute , a ... winners for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, ... one for experiment and the other for theory in nanotechnology. Prof. Markus J. ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... 19, 2016 There is no ... given the relentless pressures in pricing and lack in ... investors circle though - numerous opportunities are up for ... session, ActiveWallSt.com,s presents four names in this sector: Portola ... Inc. (NASDAQ: VTAE ), Anthera Pharmaceuticals Inc. ...
(Date:5/18/2016)... ... ... Tech Coast Angels (TCA) today announced that the Angel Capital Association ... Summit last week in Philadelphia. , The award recognizes the single-most ingenious ... is the highest honor available for an early-stage company to receive from the Angel ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):